No Data
Guangdong Zhongsheng Pharmaceutical (002317.SZ): the existing product Fumarate Chloramphenicol oral solution is a pediatric-specific dosage form.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on November 14th that according to the "Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis (2020)", oral anti-histamines are recommended for the adjunctive treatment of atopic dermatitis itch as described in the systemic treatment section. The company's current product, Chlorpheniramine Maleate Oral Solution, is a pediatric exclusive formulation. The company is also actively focusing on the research, development, production, and sales of pediatric medication varieties.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Antibiotic varieties include cefaclor dispersible tablets, cephalexin capsules, cefradine capsules, doxycycline hydrochloride tablets and other products
On November 14, Guosun Pharmaceutical (002317.SZ) stated on the investor interaction platform that the products used to treat Mycoplasma pneumoniae pneumonia, as well as symptoms such as fever, cough, headache, and sore throat caused by diseases, include: Azithromycin granules, Zhongsheng Pills series, Ibuprofen tablets, Paracetamol tablets, Zhike Pi Pa Gao, etc. The company's antibiotic varieties include Cefprozil dispersible tablets, Cefadroxil capsules, Cephradine capsules, Doxycycline Hydrochloride tablets, and other products.
Zhongsheng Pharmaceutical's Unit Gets Nod to Increase Specifications of Mucus Regulator Drug
Guangdong Zhongsheng Pharmaceutical: Approved for the supplementary application of carmetocin oral solution pharmaceutical.
Gelonghui on November 8th | guangdong zhongsheng pharmaceutical announced that its wholly-owned subsidiary Guangdong Southern Pharmaceutical Group Co., Ltd. recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for the carmosmond solution for oral administration. Carmosmond oral solution is used to treat patients with thick sputum and difficulty sputum expectoration caused by chronic bronchitis, bronchial asthma, and other diseases. It is a Category B drug in the national essential drug list and medical insurance catalog.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Currently, there are no domestic products on the market for yellow body decapitated gel products.
Gelonghui November 6th | Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform that there are currently no domestically produced products on the market for its luteal gel products.
Guangdong Zhongsheng Pharmaceutical (002317): Short-term performance under pressure, it is recommended to pay attention to the progress of the innovation pipeline.
Investment Highlights: Event: The company released the 2024 third-quarter report 2024Q1-3: Achieved revenue of 1.91 billion yuan, a year-on-year decrease of 7.9%, achieved net income attributable to mother of 0.15 billion yuan, a year-on-year decrease of 46.8%, achieved deductions
No Data
No Data